These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 9033651

  • 1. Pleiotropic over-expression of multidrug-resistance-related genes is correlated to MYCN and max mRNA accumulation during tumour progression in the IGR-N-91 human neuroblastoma model.
    Cappellen D, Bénard J.
    Int J Cancer; 1997 Feb 07; 70(4):430-6. PubMed ID: 9033651
    [Abstract] [Full Text] [Related]

  • 2. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
    Raschella G, Romeo A, Negroni A, Pucci S, Dominici C, Castello MA, Bevilacqua P, Felsani A, Calabretta B.
    Cancer Res; 1994 Apr 15; 54(8):2251-5. PubMed ID: 8174135
    [Abstract] [Full Text] [Related]

  • 3. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
    Blanc E, Goldschneider D, Ferrandis E, Barrois M, Le Roux G, Leonce S, Douc-Rasy S, Bénard J, Raguénez G.
    Am J Pathol; 2003 Jul 15; 163(1):321-31. PubMed ID: 12819037
    [Abstract] [Full Text] [Related]

  • 4. The mycN/max protein complex in neuroblastoma. Short review.
    Wenzel A, Schwab M.
    Eur J Cancer; 1995 Jul 15; 31A(4):516-9. PubMed ID: 7576956
    [Abstract] [Full Text] [Related]

  • 5. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
    Smith AG, Popov N, Imreh M, Axelson H, Henriksson M.
    J Cell Biochem; 2004 Aug 15; 92(6):1282-95. PubMed ID: 15258910
    [Abstract] [Full Text] [Related]

  • 6. A dominant-negative mutant of Max that inhibits sequence-specific DNA binding by Myc proteins.
    Billaud M, Isselbacher KJ, Bernards R.
    Proc Natl Acad Sci U S A; 1993 Apr 01; 90(7):2739-43. PubMed ID: 8464883
    [Abstract] [Full Text] [Related]

  • 7. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse.
    Ferrandis E, Da Silva J, Riou G, Bénard I.
    Cancer Res; 1994 Apr 15; 54(8):2256-61. PubMed ID: 8174136
    [Abstract] [Full Text] [Related]

  • 8. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells.
    Wenzel A, Cziepluch C, Hamann U, Schürmann J, Schwab M.
    EMBO J; 1991 Dec 15; 10(12):3703-12. PubMed ID: 1935896
    [Abstract] [Full Text] [Related]

  • 9. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
    Spengler BA, Lazarova DL, Ross RA, Biedler JL.
    Oncol Res; 1997 Dec 15; 9(9):467-76. PubMed ID: 9495452
    [Abstract] [Full Text] [Related]

  • 10. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
    Kolfschoten GM, Hulscher TM, Pinedo HM, Boven E.
    Br J Cancer; 2000 Oct 15; 83(7):921-7. PubMed ID: 10970695
    [Abstract] [Full Text] [Related]

  • 11. Myc meets its Max.
    Cole MD.
    Cell; 1991 May 31; 65(5):715-6. PubMed ID: 2040011
    [No Abstract] [Full Text] [Related]

  • 12. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
    Eijdems EW, Zaman GJ, de Haas M, Versantvoort CH, Flens MJ, Scheper RJ, Kamst E, Borst P, Baas F.
    Br J Cancer; 1995 Aug 31; 72(2):298-306. PubMed ID: 7640209
    [Abstract] [Full Text] [Related]

  • 13. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
    Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SP, Kuwano M.
    Br J Cancer; 1995 May 31; 71(5):907-13. PubMed ID: 7734314
    [Abstract] [Full Text] [Related]

  • 14. Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions.
    Peverali FA, Orioli D, Tonon L, Ciana P, Bunone G, Negri M, Della-Valle G.
    Oncogene; 1996 Jan 18; 12(2):457-62. PubMed ID: 8570225
    [Abstract] [Full Text] [Related]

  • 15. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X, Giap C, Lazo JS, Prochownik EV.
    Oncogene; 2003 Sep 18; 22(40):6151-9. PubMed ID: 13679853
    [Abstract] [Full Text] [Related]

  • 16. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM.
    Cancer Res; 2003 Apr 01; 63(7):1631-5. PubMed ID: 12670915
    [Abstract] [Full Text] [Related]

  • 17. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
    Zhao X, Li D, Pu J, Mei H, Yang D, Xiang X, Qu H, Huang K, Zheng L, Tong Q.
    Oncogene; 2016 Jul 07; 35(27):3565-76. PubMed ID: 26549029
    [Abstract] [Full Text] [Related]

  • 18. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.
    Zervos AS, Gyuris J, Brent R.
    Cell; 1993 Jan 29; 72(2):223-32. PubMed ID: 8425219
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.